Alkermes PLC (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,000 shares of Alkermes stock in a transaction on Friday, December 1st. The shares were sold at an average price of $51.98, for a total value of $51,980.00. Following the completion of the sale, the director now owns 9,000 shares in the company, valued at approximately $467,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Alkermes PLC (NASDAQ:ALKS) traded up $1.41 during trading hours on Friday, hitting $53.70. The stock had a trading volume of 1,686,908 shares, compared to its average volume of 902,468. Alkermes PLC has a twelve month low of $46.42 and a twelve month high of $63.40. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23.
Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Thursday, October 26th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. The business had revenue of $217.40 million during the quarter, compared to analysts’ expectations of $231.29 million. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The business’s quarterly revenue was up 20.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.09) EPS. research analysts forecast that Alkermes PLC will post -0.59 earnings per share for the current year.
Several large investors have recently added to or reduced their stakes in ALKS. Dimensional Fund Advisors LP boosted its position in shares of Alkermes by 1.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 194,531 shares of the company’s stock worth $11,381,000 after acquiring an additional 2,891 shares in the last quarter. Capstone Asset Management Co. boosted its position in shares of Alkermes by 2.6% in the 2nd quarter. Capstone Asset Management Co. now owns 6,755 shares of the company’s stock valued at $392,000 after purchasing an additional 170 shares during the period. Aperio Group LLC boosted its position in shares of Alkermes by 3.2% in the 2nd quarter. Aperio Group LLC now owns 25,440 shares of the company’s stock valued at $1,475,000 after purchasing an additional 782 shares during the period. US Bancorp DE boosted its position in shares of Alkermes by 366.4% in the 2nd quarter. US Bancorp DE now owns 3,974 shares of the company’s stock valued at $231,000 after purchasing an additional 3,122 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of Alkermes in the 2nd quarter valued at about $554,000. 99.75% of the stock is owned by institutional investors and hedge funds.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
What are top analysts saying about Alkermes PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alkermes PLC and related companies.